JP2016088929A - Pollution preventing agent, and pollution preventing cosmetic or pollution preventing skin external preparation including the same - Google Patents
Pollution preventing agent, and pollution preventing cosmetic or pollution preventing skin external preparation including the same Download PDFInfo
- Publication number
- JP2016088929A JP2016088929A JP2015195544A JP2015195544A JP2016088929A JP 2016088929 A JP2016088929 A JP 2016088929A JP 2015195544 A JP2015195544 A JP 2015195544A JP 2015195544 A JP2015195544 A JP 2015195544A JP 2016088929 A JP2016088929 A JP 2016088929A
- Authority
- JP
- Japan
- Prior art keywords
- zinc
- amino acids
- pollution preventing
- pollution
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 17
- 239000002537 cosmetic Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 29
- 150000003751 zinc Chemical class 0.000 claims abstract description 49
- 150000001413 amino acids Chemical class 0.000 claims abstract description 37
- 238000003915 air pollution Methods 0.000 claims abstract description 11
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 claims abstract description 9
- 108090001007 Interleukin-8 Proteins 0.000 claims abstract description 8
- 239000000356 contaminant Substances 0.000 claims abstract description 7
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 5
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims abstract 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims abstract 2
- 210000001339 epidermal cell Anatomy 0.000 claims description 24
- 238000011109 contamination Methods 0.000 claims description 14
- 230000006698 induction Effects 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002519 antifouling agent Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 16
- 239000011701 zinc Substances 0.000 abstract description 16
- 229910052725 zinc Inorganic materials 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 10
- 210000002345 respiratory system Anatomy 0.000 abstract description 2
- 230000037380 skin damage Effects 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 23
- -1 sulfur dioxide) Chemical compound 0.000 description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 239000003344 environmental pollutant Substances 0.000 description 12
- 231100000719 pollutant Toxicity 0.000 description 12
- 238000010186 staining Methods 0.000 description 11
- HGSXDBRNFBJIMX-UHFFFAOYSA-N 2-aminoacetic acid;zinc Chemical compound [Zn].NCC(O)=O HGSXDBRNFBJIMX-UHFFFAOYSA-N 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000013618 particulate matter Substances 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 8
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000003449 preventive effect Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 229940062776 zinc aspartate Drugs 0.000 description 6
- POEVDIARYKIEGF-CEOVSRFSSA-L zinc;(2s)-2-aminobutanedioate;hydron Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O POEVDIARYKIEGF-CEOVSRFSSA-L 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000116 mitigating effect Effects 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- DLSJEZJLUPVERH-RGMNGODLSA-N C(C)(=O)N[C@@H](CCSC)C(=O)O.[Zn] Chemical compound C(C)(=O)N[C@@H](CCSC)C(=O)O.[Zn] DLSJEZJLUPVERH-RGMNGODLSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 229940032991 zinc picolinate Drugs 0.000 description 3
- CHCZPSBPZFXDQJ-UHFFFAOYSA-L zinc;2-oxopyrrolidine-1-carboxylate Chemical compound [Zn+2].[O-]C(=O)N1CCCC1=O.[O-]C(=O)N1CCCC1=O CHCZPSBPZFXDQJ-UHFFFAOYSA-L 0.000 description 3
- NHVUUBRKFZWXRN-UHFFFAOYSA-L zinc;pyridine-2-carboxylate Chemical compound C=1C=CC=NC=1C(=O)O[Zn]OC(=O)C1=CC=CC=N1 NHVUUBRKFZWXRN-UHFFFAOYSA-L 0.000 description 3
- YICVJSOYNBZJAK-UHFFFAOYSA-N 14-methylpentadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C YICVJSOYNBZJAK-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102000001493 Cyclophilins Human genes 0.000 description 2
- 108010068682 Cyclophilins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- SUZRRICLUFMAQD-UHFFFAOYSA-N N-Methyltaurine Chemical compound CNCCS(O)(=O)=O SUZRRICLUFMAQD-UHFFFAOYSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000000809 air pollutant Substances 0.000 description 2
- 231100001243 air pollutant Toxicity 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229940078568 isocetyl myristate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 239000012855 volatile organic compound Substances 0.000 description 2
- 239000002676 xenobiotic agent Substances 0.000 description 2
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001466538 Gymnogyps Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- KVSNWFPDQKYYGY-UHFFFAOYSA-N N1=C(C)C(O)=C(CO)C(CO)=C1.C(CCCCCCCCC)(=O)O Chemical compound N1=C(C)C(O)=C(CO)C(CO)=C1.C(CCCCCCCCC)(=O)O KVSNWFPDQKYYGY-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- XJKITIOIYQCXQR-SCUNHAKFSA-N all-trans-retinyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C XJKITIOIYQCXQR-SCUNHAKFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940099417 ceramide 2 Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- ZLSFWAPBBIIMKI-KVINTPOGSA-M dipotassium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxido-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [K+].[K+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H]([O-])C1(C)C ZLSFWAPBBIIMKI-KVINTPOGSA-M 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 229940099578 hydrogenated soybean lecithin Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000000791 photochemical oxidant Substances 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000621 toxification Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- ORCZNRDIGZRGLV-DKWTVANSSA-L zinc;(2s)-2-aminobutanedioate Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC([O-])=O ORCZNRDIGZRGLV-DKWTVANSSA-L 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、アミノ酸類の亜鉛塩及び／又は亜鉛錯体を有効成分とする汚染防止剤、並びにその汚染防止剤を含有する汚染防止用化粧料又は汚染防止用皮膚外用剤に関する。 The present invention relates to a contamination preventive agent comprising a zinc salt of amino acids and / or a zinc complex as an active ingredient, and a contamination preventive cosmetic or a skin preventive external preparation containing the contamination preventive agent.
大気汚染は、種々の型の化学物質及び／又は生体異物及び粒子から成り、主要な物質としては、自動車、火力発電所、焼却炉、暖炉などの排煙、火山噴火による噴出物、土壌粒子などが由来の粒子状物質（ＰＭ）、粉塵、燃焼などが由来の一酸化炭素、硫黄酸化物（二酸化硫黄など）、窒素酸化物（二酸化窒素など）などの排出ガス、炭化水素と窒素酸化物などが光化学反応を起こして生じるオゾン（Ｏ３）や多環芳香族炭化水素（ＰＡＨｓ）などの光化学オキシダント、燃焼や石油製品からの揮発などが由来の揮発性有機化合物（ＶＯＣ）（ホルムアルデヒドなどのアルデヒド類、ＰＡＨ、ダイオキシン類など）などの排出ガス・微粒子、鉱物や工業製品などが由来の石綿などの微粒子が広く知られている。 Air pollution consists of various types of chemical substances and / or xenobiotics and particles, and the main substances are smoke from automobiles, thermal power plants, incinerators, fireplaces, ejecta from volcanic eruptions, soil particles, etc. Particulate matter (PM) derived from, exhaust gas such as carbon monoxide, sulfur oxide (such as sulfur dioxide), nitrogen oxide (such as nitrogen dioxide) derived from dust, combustion, etc., hydrocarbon and nitrogen oxide, etc. Photochemical oxidants such as ozone (O3) and polycyclic aromatic hydrocarbons (PAHs) generated by photochemical reaction of volatile organic compounds (VOC) derived from combustion and volatilization from petroleum products (aldehydes such as formaldehyde) , PAH, dioxins, etc.), and fine particles such as asbestos derived from minerals and industrial products are widely known.
実際、日本では大気汚染防止法により、それらの多くが規制の対象となっており、排出基準等が定められるなど、対策が講じられている。しかしながら、粒子状物質（ＰＭ）に関しては、近隣諸国から越境輸送されてくることが、日本周辺で昨今非常に深刻な問題となりつつある。なお、大気汚染防止法では法規制の対象である粒子状物質として「自動車排ガスの中の粒子状物質」を指定しており、同法関連法規では粒子状物質が「自動車排ガスの中の粒子状物質」に限定して用いられている。 In fact, in Japan, many of them are subject to regulation under the Air Pollution Control Law, and measures are taken such as establishing emission standards. However, with regard to particulate matter (PM), cross-border transport from neighboring countries is becoming a very serious problem around Japan. The Air Pollution Control Act designates “particulate matter in automobile exhaust gas” as the particulate matter subject to laws and regulations, and the relevant laws and regulations specify that particulate matter is “particulate matter in automobile exhaust gas”. It is limited to “substance”.
これら大気汚染の原因とされる種々の型の化学物質及び／又は生体異物及び粒子の人体に対する影響としては、直接吸入する恐れがあることから、呼吸器系に対する影響は広く論ぜられてきた。一方、皮膚は生体における最外層の臓器であり常に外界に曝されていることから、呼吸器系同様にして、大気汚染物質に直接接触する可能性を潜在的に有している。 The effects on the human body of these various types of chemical substances and / or xenobiotics and particles that are responsible for air pollution have been widely discussed because of the potential for direct inhalation. On the other hand, since the skin is the outermost organ in the living body and is always exposed to the outside world, it has the potential to come into direct contact with air pollutants like the respiratory system.
ところで、大気汚染物質、例えばタバコの煙は窒素酸化物あるいは活性酸素種の生成を介して、皮膚におけるしわの形成や透明度の低下、あるいは乾癬との関連が報告されている。また、オゾンは過酸化脂質の生成を介した角層の機能障害、あるいは炎症性マーカーであるシクロオキシゲナーゼ−２（ＣＯＸ−２）を誘導することが知られている（非特許文献１）。さらに、重金属は、必須の栄養素として生体維持に必要な一方で、それらが生理学的な濃度にない場合、すなわち、環境中の過量の金属に曝露されると有毒な作用が生じる可能性がある。大気中に存在する金属の量は増加しつつあり、この結果汚染された食品の摂取及び大気中の金属への曝露を通じて体内の重金属濃度は増加し、タンパク質の３次及び４次構造が損傷を与える可能性がある。その結果、触媒活性が低下、傷ついたタンパク質が抗原となり免疫反応を生じる可能性がある。さらに、いくつかの重金属は皮膚を透過しかつ蓄積されることが示されてきた（非特許文献２）。また、粒子状物質は粒子表面に多数の有機化合物、特に多ＰＡＨｓが吸着する。粒子の表面に吸着されたこれらの多環式芳香族炭化水素及び都市の空気が運搬するほこりは皮膚組織を透過することができ、そこで生物学的に形質転換される可能性がある。これらの肝臓における代謝は文献で十分に記述されており、これによりモノヒドロキシル化代謝物（解毒経路）、エポキシド及びジオールエポキシド（毒性化経路）の形成に導かれる。同様の現象を皮膚で観察することができ、ＰＡＨｓによるＣＹＰ過剰誘導は皮膚トラブルのトリガーとなることが報告されており、これらの化合物は皮膚に対して発ガン性及び免疫原性の作用を有することが知られている（非特許文献３）。 By the way, air pollutants such as cigarette smoke have been reported to be associated with the formation of wrinkles in the skin, decreased transparency, or psoriasis through the generation of nitrogen oxides or reactive oxygen species. In addition, ozone is known to induce stratum corneum dysfunction through the formation of lipid peroxide, or cyclooxygenase-2 (COX-2), which is an inflammatory marker (Non-patent Document 1). Furthermore, while heavy metals are required for living organisms as essential nutrients, toxic effects can occur when they are not in physiological concentrations, i.e., exposed to excessive amounts of metals in the environment. The amount of metals present in the atmosphere is increasing, resulting in increased concentrations of heavy metals in the body through the consumption of contaminated food and exposure to metals in the atmosphere, and damage to protein tertiary and quaternary structures. There is a possibility to give. As a result, the catalytic activity is reduced, and the damaged protein may become an antigen and cause an immune reaction. Furthermore, some heavy metals have been shown to penetrate and accumulate in the skin (Non-Patent Document 2). In addition, particulate matter adsorbs a large number of organic compounds, particularly multi-PAHs, on the particle surface. Dust carried by these polycyclic aromatic hydrocarbons adsorbed on the surface of the particles and city air can penetrate skin tissue where they can be biologically transformed. The metabolism in these livers is well documented in the literature, leading to the formation of monohydroxylated metabolites (detoxification pathway), epoxides and diol epoxides (toxification pathway). Similar phenomena can be observed in the skin, and CYP over-induction by PAHs has been reported to trigger skin troubles, and these compounds have carcinogenic and immunogenic effects on the skin. It is known (Non-Patent Document 3).
本発明は、大気汚染の原因となる汚染物質が皮膚障害を引き起こすことを防止する汚染防止剤、ならびにこの汚染防止剤を含有する汚染防止用化粧料又は汚染防止用皮膚外用剤を提供することを課題とする。 It is an object of the present invention to provide a contamination preventive agent that prevents a pollutant that causes air pollution from causing skin damage, and a contamination-preventing cosmetic or a contamination-preventing skin external preparation that contains this contamination preventive agent. Let it be an issue.
本発明者らは、表皮細胞において汚染物質に起因する細胞傷害緩和作用、ＣＹＰ１過剰誘導作用、ＣＯＸ−２過剰誘導作用、ＩＬ−８過剰誘導作用を抑制することを特徴とする汚染防止剤について鋭意研究した結果、アミノ酸類の亜鉛塩及び／又は亜鉛錯体が顕著な有用性を示すことを見出し、本発明を完成するに至った。 The present inventors have earnestly studied a pollution inhibitor characterized by suppressing the cytotoxicity-reducing action, CYP1 excess induction action, COX-2 excess induction action, and IL-8 excess induction action caused by contaminants in epidermal cells. As a result of research, the inventors have found that zinc salts and / or zinc complexes of amino acids show remarkable utility, and have completed the present invention.
従来の汚染防止剤は、大気汚染の原因となる汚染物質の皮膚に対する付着および浸透防止剤、あるいは洗浄剤が主体であり、皮膚内部に浸透した汚染物質に対して効果を示すものではなかった。本発明者らは、皮膚内部に浸透した汚染物質が表皮細胞において、皮膚トラブルを惹起するメカニズムに注目し、細胞傷害緩和作用、ＣＹＰ１過剰誘導作用、ＣＯＸ−２過剰誘導作用、ＩＬ−８過剰誘導作用の抑制に対し、アミノ酸類の亜鉛塩及び／又は亜鉛錯体の顕著な有用性を見出した。また、アミノ酸類の亜鉛塩及び／又は亜鉛錯体については、表皮細胞からのサイトカイン類放出抑制を特徴とするＤＮＡ損傷あるいはマトリックスメタロプロテアーゼー１産生に対し、抑制作用を示すことで抗老化作用を示すことから（特許文献２）、汚染物質を始めとする皮膚トラブルの防止に効果的な汚染防止用化粧料および汚染防止用皮膚外用剤を提供することができる。 Conventional antifouling agents mainly consist of anti-adherent and penetrating agents or cleaning agents for pollutants that cause air pollution, and have no effect on pollutants that have penetrated into the skin. The present inventors pay attention to the mechanism by which contaminants that have penetrated into the skin cause skin troubles in epidermal cells, and they alleviate cytotoxicity, induce CYP1 excessively, induce COX-2 excessively, induce IL-8 excessively. It was found that the zinc salts of amino acids and / or zinc complexes were remarkably useful for suppressing the action. In addition, zinc salts of amino acids and / or zinc complexes exhibit an anti-aging effect by exhibiting an inhibitory action on DNA damage or matrix metalloproteinase-1 production characterized by suppression of cytokine release from epidermal cells. Therefore (Patent Document 2), it is possible to provide an anti-staining cosmetic and an anti-staining skin external agent that are effective in preventing skin troubles including contaminants.
本発明に係る大気汚染防止剤はアミノ酸類の亜鉛塩及び／又は亜鉛錯体を有効成分とするもので、化粧料および皮膚外用剤として皮膚表面に適用されることで、その効果を発現するものである。 The air pollution inhibitor according to the present invention comprises an amino acid zinc salt and / or zinc complex as an active ingredient, and exhibits its effect when applied to the skin surface as a cosmetic or skin external preparation. is there.
本発明で用いるアミノ酸類の亜鉛塩は、アミノ酸類と亜鉛の塩であり、アミノ酸類の亜鉛錯体は、配位結合を介してアミノ酸類が亜鉛に結合したアミノ酸類の亜鉛錯体である。アミノ酸類の亜鉛塩及び亜鉛錯体は、公知のアミノ酸類と亜鉛塩から調製することが出来る（特許文献１）。本発明においては、アミノ酸類の亜鉛塩、アミノ酸類の亜鉛錯体が、それぞれ単独でまたは混合して用いる事ができる。 The zinc salt of amino acids used in the present invention is a salt of amino acids and zinc, and the zinc complex of amino acids is a zinc complex of amino acids in which the amino acids are bonded to zinc via a coordination bond. Zinc salts and zinc complexes of amino acids can be prepared from known amino acids and zinc salts (Patent Document 1). In the present invention, zinc salts of amino acids and zinc complexes of amino acids can be used alone or in combination.
また、アミノ酸類としては、亜鉛と塩もしくは錯体を形成し得るアミノ酸類であれば中性アミノ酸、塩基性アミノ酸、酸性アミノ酸のいずれでも良く、例えば、グリシン、システイン、アラニン、セリン、ジェンコール酸、γ―アミノ酪酸、トレオニン、バリン、メチオニン、ロイシン、イソロイシン、フェニルアラニン、チロシン、チロキシン、プロリン、ヒドロキシプロリン、トリプトファン、タウリン、グルタミン酸、アスパラギン酸、アルギニン、ＤＬ―ピロリドンカルボン酸、リジン、オルニチン、ヒスチジン、タウリン、Ｎ−メチルタウリン等が挙げられ、これらはＤ体、Ｌ体、ＤＬ体の何れであっても良い。また、これらのアミノ酸類の亜鉛塩及び／又は亜鉛錯体に用いられるアミノ酸は、更に誘導体化されていても良く、例えば、Ｎ−アシルアミノ酸、Ｎ−アルキルアミノ酸、Ｎ，Ｎ−ジアルキルアミノ酸、Ｓ−アルキルアミノ酸、及びアミノ酸エステル等を挙げることができる。 The amino acids may be neutral amino acids, basic amino acids, or acidic amino acids as long as they can form a salt or complex with zinc. For example, glycine, cysteine, alanine, serine, jencolic acid, γ-aminobutyric acid, threonine, valine, methionine, leucine, isoleucine, phenylalanine, tyrosine, thyroxine, proline, hydroxyproline, tryptophan, taurine, glutamic acid, aspartic acid, arginine, DL-pyrrolidone carboxylic acid, lysine, ornithine, histidine, taurine N-methyltaurine and the like, and these may be any of D-form, L-form and DL-form. In addition, amino acids used in zinc salts and / or zinc complexes of these amino acids may be further derivatized, such as N-acyl amino acids, N-alkyl amino acids, N, N-dialkyl amino acids, S- Examples include alkyl amino acids and amino acid esters.
本発明におけるアミノ酸類の亜鉛塩のうち、好ましいものとしては、グリシン亜鉛塩、アスパラギン酸亜鉛塩、ピロリドンカルボン酸亜鉛、システイン亜鉛塩、スレオニン亜鉛塩、バリン亜鉛塩、アセチルメチオニン亜鉛、ピコリン酸亜鉛等が挙げられ、特に好ましいものとしては、グリシン亜鉛塩、アスパラギン酸亜鉛塩、ピロリドンカルボン酸亜鉛塩が挙げられる。アミノ酸類の亜鉛錯体のうち、好ましいものとしては、グリシン亜鉛錯体、アスパラギン酸亜鉛錯体、ピロリドンカルボン酸亜鉛錯体、システイン亜鉛錯体、スレオニン亜鉛錯体、バリン亜鉛錯体、アセチルメチオニン亜鉛錯体、ピコリン酸亜鉛錯体等が挙げられ、特に好ましいものとしては、グリシン亜鉛錯体、アスパラギン酸亜鉛錯体、ピロリドンカルボン酸亜鉛錯体が挙げられる。これらのアミノ酸類の亜鉛塩及び／又は亜鉛錯体は１種又は２種以上を組み合わせて用いることができる。市販品としては、例えば、日光ケミカルズ社のグリシン亜鉛コンプレックス（グリシン亜鉛錯体）、やセピック社のＧＩＶＯＢＩＯ ＡＺｎＬ（アスパラギン酸亜鉛）、ソラビア社のＺｉｎｃｉｄｏｎｅ（ピロリドンカルボン酸亜鉛）等があるのでこれを利用してもよく、これらの市販品を処理したものを利用することもできる。 Among the zinc salts of amino acids in the present invention, preferred are glycine zinc salt, zinc aspartate, zinc pyrrolidonecarboxylate, cysteine zinc salt, threonine zinc salt, valine zinc salt, acetylmethionine zinc, zinc picolinate and the like. Particularly preferred are glycine zinc salt, aspartic acid zinc salt, and pyrrolidone carboxylic acid zinc salt. Among the zinc complexes of amino acids, preferred are glycine zinc complex, zinc aspartate complex, zinc pyrrolidonecarboxylate, cysteine zinc complex, threonine zinc complex, valine zinc complex, acetylmethionine zinc complex, zinc picolinate complex, etc. Particularly preferred are glycine zinc complex, zinc aspartate complex, and zinc pyrrolidonecarboxylate complex. The zinc salts and / or zinc complexes of these amino acids can be used alone or in combination of two or more. Commercially available products include, for example, Nikko Chemicals Glycine Zinc Complex (Glycine Zinc Complex), Sepic GIVOBIO AZnL (Zinc Aspartate), Soravia Zincidone (Zinc Pyrrolidone Carboxylate) and so on. It is also possible to use a product obtained by processing these commercially available products.
本汚染防止剤の化粧料および皮膚外用剤への配合量は、用途、剤型、配合目的等によって異なり、特に限定されるものではないが、一般的には、アミノ酸類の亜鉛塩及び／又は亜鉛錯体の原体として、外用剤中０．００１〜１０．０質量％が好ましく、より好ましくは０．０１〜５．０質量％である。 The blending amount of the antifouling agent in cosmetics and external preparations for skin varies depending on the use, dosage form, blending purpose, etc., and is not particularly limited, but in general, zinc salts of amino acids and / or As a base of a zinc complex, 0.001-10.0 mass% is preferable in an external preparation, More preferably, it is 0.01-5.0 mass%.
本汚染防止剤を含む汚染防止用化粧料および汚染防止用皮膚外用剤には、既存の抗炎症剤、肌荒れ予防／改善剤、色素沈着予防／改善剤を配合することができる。これらの成分を併用することは、本効果の相乗効果をもたらし、本効果を損なうものではない。 An existing anti-inflammatory agent, rough skin preventing / improving agent, and pigmentation preventing / improving agent can be blended in the anti-staining cosmetic and the anti-staining skin external preparation containing the present anti-staining agent. The combined use of these components brings about a synergistic effect of this effect and does not impair this effect.
さらに、本汚染防止剤を配合した汚染防止用化粧料および汚染防止用皮膚外用剤には、本発明の効果を損なわない範囲で化粧品、医薬部外品等に配合されうる成分を任意に配合することができ、例えば、流動パラフィンなどの炭化水素、植物油脂、ロウ類、合成エステル油、シリコーン系の油相成分、フッ素系の油相成分、高級アルコール類、脂肪酸類、増粘剤、紫外線吸収剤、粉体、顔料、色材、陰イオン性界面活性剤、陽イオン性界面活性剤、非イオン性界面活性剤、両性界面活性剤、多価アルコール、糖、高分子化合物、生理活性成分、経皮吸収促進剤、溶媒、酸化防止剤、香料、防腐剤等がある。 Furthermore, the anti-staining cosmetic and the anti-staining skin external preparation containing this anti-staining agent optionally contain ingredients that can be added to cosmetics, quasi-drugs, etc. within the range that does not impair the effects of the present invention. For example, hydrocarbons such as liquid paraffin, vegetable oils and fats, waxes, synthetic ester oils, silicone oil phase components, fluorine oil phase components, higher alcohols, fatty acids, thickeners, UV absorption Agent, powder, pigment, coloring material, anionic surfactant, cationic surfactant, nonionic surfactant, amphoteric surfactant, polyhydric alcohol, sugar, polymer compound, physiologically active ingredient, There are transdermal absorption accelerators, solvents, antioxidants, fragrances, preservatives and the like.
本汚染防止剤を配合した汚染防止用化粧料および汚染防止用皮膚外用剤に係る剤型は任意であり、化粧水、ローション、乳液、クリーム、パック、軟膏、分散液、固形物、ムース等の任意の剤型をとることができる。また、用途としては、化粧料の他、皮膚外用剤、医薬用軟膏等に好適に使用できる。 The dosage form of the anti-staining cosmetic and the anti-staining skin preparation formulated with the anti-staining agent is arbitrary, such as lotions, lotions, emulsions, creams, packs, ointments, dispersions, solids, mousses, etc. Any dosage form can be taken. In addition to cosmetics, it can be suitably used for skin external preparations, pharmaceutical ointments and the like.
以下に実施例を挙げて本発明を具体的に説明するが、本発明の技術的範囲がこれらに限定されるものではない。 EXAMPLES The present invention will be specifically described below with reference to examples, but the technical scope of the present invention is not limited to these examples.
汚染物質による表皮細胞の細胞傷害に対する緩和作用
１、試験の概要
汚染物質曝露による表皮細胞の細胞傷害に対する、各種アミノ酸類の亜鉛塩及び／又は亜鉛錯体の緩和作用を評価した。汚染物質のモデル化合物として、Nａｔｉｏｎａｌ Ｉｎｓｔｉｔｕｔｅ ｏｆ Ｓｔａｎｄａｒｄｓ ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ（ＮＩＳＴ）から入手したＳｔａｎｄａｒｄ Ｒｅｆｅｒｅｎｃｅ Ｍａｔｅｒｉａｌｓ（ＳＲＭ）１９７５を用いて評価を行った。ＳＲＭ１９７５の詳細については、ＮＩＳＴのウェブサイトより入手可能である。
Mitigating action against cytotoxicity of epidermal cells by pollutants 1. Outline of test The mitigating action of zinc salts and / or zinc complexes of various amino acids on the cytotoxicity of epidermal cells caused by exposure to pollutants was evaluated. Evaluation was performed using Standard Reference Materials (SRM) 1975 obtained from National Institute of Standards and Technology (NIST) as a model compound of pollutants. Details of SRM 1975 are available from the NIST website.
２、実験方法
表皮細胞に対して表１に記載の試料およびＳＲＭ１９７５を添加し、２４時間培養した。その後、表皮細胞の生存率をＭＴＴ法により検出し、各試料の緩和作用を、試料およびＳＲＭ１９７５未処理細胞に対する生存率で評価した。
2. Experimental method Samples listed in Table 1 and SRM1975 were added to epidermal cells and cultured for 24 hours. Thereafter, the survival rate of the epidermal cells was detected by the MTT method, and the mitigating action of each sample was evaluated by the survival rate with respect to the sample and SRM1975-untreated cells.
３、結果
結果を表１に示した。ＳＲＭ１９７５未処理での表皮細胞の生存率を比較対象として、アミノ酸類の亜鉛塩及び／又は亜鉛錯体６．３〜５０μｍｏｌ／ＬとＳＲＭ１９７５の混合物を処理した表皮細胞の残存率は、ＳＲＭ１９７５のみ（アミノ酸類の亜鉛塩及び／又は亜鉛錯体が０．００ｍｍｏｌ／Ｌ）を処理した表皮細胞の残存率に比べて、有意に細胞残存率が向上した。つまり、いずれのアミノ酸類の亜鉛塩及び／又は亜鉛錯体においても、ＳＲＭ１９７５処理による細胞傷害に対する緩和作用が認められた。アミノ酸類の亜鉛塩及び／又は亜鉛錯体の中でも、特にグリシン亜鉛錯体に優れた効果が認められた。
3. Results The results are shown in Table 1. The survival rate of epidermal cells treated with a mixture of amino acid zinc salt and / or zinc complex 6.3-50 μmol / L and SRM1975 was compared with the survival rate of epidermal cells not treated with SRM1975. Compared to the survival rate of epidermal cells treated with a zinc salt and / or zinc complex of 0.00 mmol / L), the cell survival rate was significantly improved. In other words, any of the amino acid zinc salts and / or zinc complexes was found to have a mitigating effect on cell damage due to treatment with SRM1975. Among zinc salts of amino acids and / or zinc complexes, particularly excellent effects were observed on glycine zinc complexes.
汚染物質による表皮細胞のＣＹＰ１過剰誘導に対する抑制作用
１、試験の概要
汚染物質曝露による表皮細胞のＣＹＰ１過剰誘導に対する、各種アミノ酸類の亜鉛塩及び／又は亜鉛錯体の抑制作用を評価した。
Suppressive action on CYP1 over-induction of epidermal cells by pollutants 1. Outline of test The inhibitory action of zinc salts and / or zinc complexes of various amino acids on CYP1 over-induction of epidermal cells by exposure to pollutants was evaluated.
２、実験方法
表皮細胞に対して表２に記載の試料およびＳＲＭ１９７５を添加し、２４時間培養した。その後、Ｒｅａｌｔｉｍｅ ＲＴ−ＰＣＲ法（Ａｐｐｌｉｅｄ Ｂｉｏｓｙｓｔｅｍ社）により、ＣＹＰ１の遺伝子発現を評価した。なお、内部標準物質としてＣｙｃｌｏｐｈｉｌｌｉｎを用い、ΔΔＣＴ法により解析を行った。各試料のＣＹＰ１誘導抑制作用を、試料およびＳＲＭ１９７５未処理細胞に対する発現比で評価した。
2. Experimental method Samples described in Table 2 and SRM1975 were added to epidermal cells and cultured for 24 hours. Then, the gene expression of CYP1 was evaluated by Realtime RT-PCR method (Applied Biosystem). The analysis was performed by the ΔΔCT method using Cyclophilin as an internal standard substance. The CYP1-induced inhibitory action of each sample was evaluated by the expression ratio relative to the sample and SRM1975-untreated cells.
３、結果
結果を表２に示した。いずれのアミノ酸類の亜鉛塩及び／又は亜鉛錯体においても、ＳＲＭ１９７５処理によるＣＹＰ１に対する誘導抑制作用が認められた。
3. Results The results are shown in Table 2. In any of the zinc salts and / or zinc complexes of amino acids, an induction inhibitory action on CYP1 by SRM1975 treatment was observed.
汚染物質による表皮細胞のＣＯＸ−２過剰誘導に対する抑制作用
１、試験の概要
汚染物質曝露による表皮細胞のＣＯＸ−２過剰誘導に対する、各種アミノ酸類の亜鉛塩及び／又は亜鉛錯体の抑制作用を評価した。
Suppressive action against COX-2 over-induction of epidermal cells by pollutants 1. Outline of the test The inhibitory action of zinc salts and / or zinc complexes of various amino acids on COX-2 over-induction of epidermal cells by exposure to pollutants was evaluated. .
２、実験方法
表皮細胞に対して表３に記載の試料およびＳＲＭ１９７５を添加し、２４時間培養した。その後、Ｒｅａｌｔｉｍｅ ＲＴ−ＰＣＲ法（Ａｐｐｌｉｅｄ Ｂｉｏｓｙｓｔｅｍ社）により、ＣＯＸ−２の遺伝子発現を評価した。なお、内部標準物質としてＣｙｃｌｏｐｈｉｌｌｉｎを用い、ΔΔＣＴ法により解析を行った。各試料のＣＯＸ−２誘導抑制作用を、試料およびＳＲＭ１９７５未処理細胞に対する発現比で評価した。
2. Experimental method Samples described in Table 3 and SRM1975 were added to epidermal cells, and cultured for 24 hours. Subsequently, COX-2 gene expression was evaluated by Realtime RT-PCR (Applied Biosystem). The analysis was performed by the ΔΔCT method using Cyclophilin as an internal standard substance. The COX-2 induction inhibitory action of each sample was evaluated by the expression ratio relative to the sample and SRM1975-untreated cells.
３、結果
結果を表３に示した。いずれのアミノ酸類の亜鉛塩及び／又は亜鉛錯体においても、ＳＲＭ１９７５処理によるＣＯＸ−２に対する誘導抑制作用が認められた。
3. Results The results are shown in Table 3. In any of the zinc salts and / or zinc complexes of amino acids, an induction suppressing action on COX-2 by SRM1975 treatment was observed.
汚染物質による表皮細胞のＩＬ−８過剰誘導に対する抑制作用
１、試験の概要
汚染物質曝露による表皮細胞のＩＬ−８過剰誘導に対する、各種アミノ酸類の亜鉛塩及び／又は亜鉛錯体の抑制作用を評価した。
Suppressive effect of IL-8 over-induction of epidermal cells by pollutants 1. Outline of the test The inhibitory action of zinc salts of various amino acids and / or zinc complexes on IL-8 over-induction of epidermal cells by exposure to pollutants was evaluated. .
２、実験方法
表皮細胞に対して表４に記載の試料およびＳＲＭ１９７５を添加し、２４時間培養した。その後、ＥＬＩＳＡ法（Ｒ＆Ｄ Ｓｙｓｔｅｍ社）により、ＩＬ−８の放出量を評価した。
2. Experimental method Samples described in Table 4 and SRM1975 were added to epidermal cells and cultured for 24 hours. Thereafter, the amount of IL-8 released was evaluated by ELISA (R & D System).
３、結果
結果を表４に示した。いずれのアミノ酸類の亜鉛塩及び／又は亜鉛錯体においても、ＳＲＭ１９７５処理によるＩＬ−８に対する過剰誘導抑制作用が認められた。
3. Results The results are shown in Table 4. In any of the zinc salts and / or zinc complexes of amino acids, an excessive induction inhibitory action on IL-8 by SRM1975 treatment was observed.
以下に、本発明の汚染防止剤を配合した汚染防止用化粧用および汚染防止用皮膚外用剤の応用例を示す。配合量は質量％である。実施例５〜１２は、いずれも実施例１〜４に記載の評価方法により、汚染物質曝露による表皮細胞傷害の抑制効果が確認された。 Below, the application example of the cosmetics for pollution prevention which mix | blended the pollution inhibitor of this invention and the skin external preparation for pollution prevention is shown. A compounding quantity is the mass%. In each of Examples 5 to 12, the effect of suppressing epidermal cell injury due to exposure to contaminants was confirmed by the evaluation methods described in Examples 1 to 4.
汚染防止用化粧水
Ａ グリシン亜鉛錯体 ０．５（質量％）
アスパラギン酸亜鉛塩 ０．５
クエン酸 ０．４
クエン酸ナトリウム ２．０
精製水 残部
Ｂ カモミラエキス ０．１
コンドルスクリスプスエキス ０．１
シソエキス ０．１
アルギニン ０．１
Ｌ−アスコルビン酸−２−リン酸マグネシウム ０．１
ヒアルロン酸ナトリウム ０．２
１，３−ブチレングリコール ３．０
精製水 １０．０
Ｃ エチルアルコール １０．０
防腐剤 適量
香料 適量
（調製方法）Ａを加温し均一に溶解した後に、Ｂ、Ｃを加え調製を終了する。
Contamination prevention lotion A glycine zinc complex 0.5 (mass%)
Zinc aspartate 0.5
Citric acid 0.4
Sodium citrate 2.0
Purified water balance B chamomile extract 0.1
Condor crisp extract 0.1
Perilla extract 0.1
Arginine 0.1
L-ascorbic acid-2-magnesium phosphate 0.1
Sodium hyaluronate 0.2
1,3-butylene glycol 3.0
Purified water 10.0
C ethyl alcohol 10.0
Preservative Appropriate amount Perfume Appropriate amount (Preparation method) A is heated and uniformly dissolved, and then B and C are added to complete the preparation.
汚染防止用保湿化粧水
Ａ トリ（カプリル酸・カプリン酸）グリセリル ０．１（質量％）
ＰＯＰ（４）ＰＯＥ（２０）セチルエーテル ０．６
プロピレングリコール １０．０
Ｂ 精製水 ２０．０
Ｃ グリシン亜鉛錯体 ０．５
アセチルメチオニン亜鉛錯体 ０．５
システイン亜鉛錯体 ０．５
ピロリドンカルボン酸亜鉛錯体 ０．５
グリチルレチン酸ジカリウム ０．２
ギガルチナステラータエキス ０．２
ブドウエキス ０．００１
エルゴチオネイン ０．００１
リンゴ酸 ０．１
クエン酸 ０．５
クエン酸ナトリウム ０．５
ヒアルロン酸ナトリウム ０．１
防腐剤 適量
精製水 残部
（調製方法）Ａ、Ｂそれぞれ４０℃に加温し、均一に溶解する。Ａを撹拌しながら、Ｂを添加し、均一になるまで撹拌後、Ｃを添加し、室温まで冷却し調製を終了する。
Moisturizing lotion A for contamination prevention Tri (caprylic acid / capric acid) glyceryl 0.1 (mass%)
POP (4) POE (20) cetyl ether 0.6
Propylene glycol 10.0
B Purified water 20.0
C Glycine zinc complex 0.5
Acetylmethionine zinc complex 0.5
Cysteine zinc complex 0.5
Pyrrolidonecarboxylate zinc complex 0.5
Dipotassium glycyrrhetinate 0.2
Gigalchinasterata extract 0.2
Grape extract 0.001
Ergothioneine 0.001
Malic acid 0.1
Citric acid 0.5
Sodium citrate 0.5
Sodium hyaluronate 0.1
Preservative Appropriate amount Purified water The remainder (preparation method) A and B are each heated to 40 ° C. and dissolved uniformly. While stirring A, B is added. After stirring until uniform, C is added and cooled to room temperature to complete the preparation.
汚染防止用乳液
Ａ スクワラン ５．０（質量％）
２−エチルヘキサン酸セチル ５．０
ベヘニルアルコール １．５
ジメチルポリシロキサン ０．５
パルミチン酸セチル ０．５
ステアリン酸 ０．５
キミルアルコール ０．１
セラミド２ ０．１
ｄ−δ−トコフェロール ０．１
油溶性トマトエキス（リコピン１％含有） ０．０１
テトラオレイン酸ＰＯＥ（４０）ソルビタン １．５
モノステアリン酸ＰＯＥ（２０）ソルビタン １．０
親油型モノステアリン酸グリセリル １．０
Ｂ プロピレングリコール ７．０
ヒスチジン亜鉛錯体 ３．０
Ｌ−アルギニン １．０
キサンタンガム ０．１
防腐剤 適量
精製水 残部
（調製方法）Ａ、Ｂそれぞれ８０℃に加温し、均一に溶解する。Ａを撹拌しながら、Ｂを添加し、均一になるまで撹拌後、室温まで冷却し調製を終了する。
Anti-contamination emulsion A Squalane 5.0 (mass%)
Cetyl 2-ethylhexanoate 5.0
Behenyl alcohol 1.5
Dimethylpolysiloxane 0.5
Cetyl palmitate 0.5
Stearic acid 0.5
Kimyl alcohol 0.1
Ceramide 2 0.1
d-δ-tocopherol 0.1
Oil-soluble tomato extract (containing 1% lycopene) 0.01
Tetraoleic acid POE (40) sorbitan 1.5
Monostearic acid POE (20) sorbitan 1.0
Lipophilic glyceryl monostearate 1.0
B propylene glycol 7.0
Histidine zinc complex 3.0
L-Arginine 1.0
Xanthan gum 0.1
Preservative appropriate amount Purified water The remainder (preparation method) A and B are each heated to 80 ° C. and dissolved uniformly. While stirring A, B is added, stirred until uniform, and then cooled to room temperature to complete the preparation.
汚染防止用美容液
Ａ 流動パラフィン １５．０（質量％）
べヘニルアルコール ４．０
ワセリン ３．０
スクワラン １．０
モノステアリン酸ＰＯＥ（２０）ソルビタン ３．０
モノラウリン酸デカグリセリル １．０
Ｂ グリシン亜鉛錯体 ０．１
クエン酸ナトリウム ０．２
クエン酸 ０．０６
キサンタンガム ０．１
１，３−ブチレングリコール １０．０
防腐剤 適量
精製水 残部
（調製方法）Ａ、Ｂそれぞれ８０℃に加温し、均一に溶解する。Ａを撹拌しながら、Ｂを添加し、均一になるまで撹拌後、室温まで冷却し調製を終了する。
Antistaining essence A liquid paraffin 15.0 (mass%)
Behenyl alcohol 4.0
Vaseline 3.0
Squalane 1.0
Monostearic acid POE (20) sorbitan 3.0
Decaglyceryl monolaurate 1.0
B Glycine zinc complex 0.1
Sodium citrate 0.2
Citric acid 0.06
Xanthan gum 0.1
1,3-butylene glycol 10.0
Preservative appropriate amount Purified water The remainder (preparation method) A and B are each heated to 80 ° C. and dissolved uniformly. While stirring A, B is added, stirred until uniform, and then cooled to room temperature to complete the preparation.
汚染防止用クリーム（エモリエントタイプ）
Ａ テトラヘキシルデカン酸アスコルビル １．０（質量％）
トリスヘキシルデカン酸ピリドキシン ０．５
ｄｌ−α−トコフェロール ０．２
パルミチン酸レチノール ０．１
水添レチノール ０．１
スクワラン １０．０
ミリスチン酸イソセチル ６．０
トリ２−エチルヘキサン酸グリセリル ３．０
マカデミアナッツ油 １．０
ジメチルポリシロキサン ０．２
セタノール ５．０
ＰＯＥ（２０）セチルエーテル １．０
テトラオレイン酸ＰＯＥ（４０）ソルビット ０．５
モノステアリン酸グリセリル １．０
水素添加大豆レシチン ０．２
Ｂ ピロリドンカルボン酸亜鉛塩 ０．０５
ヒアルロン酸ナトリウム ０．０１
キサンタンガム ０．１
１，３−ブチレングリコール ５．０
クエン酸 ０．１
クエン酸ナトリウム ０．４
防腐剤 適量
精製水 残部
（調製方法）Ａ、Ｂそれぞれ８０℃に加温し、均一に溶解する。Ａを撹拌しながら、Ｂを添加し、均一になるまで撹拌後、室温まで冷却し調製を終了する。
Anti-contamination cream (emollient type)
A Ascorbyl tetrahexyldecanoate 1.0 (mass%)
Tridohexyl decanoate pyridoxine 0.5
dl-α-tocopherol 0.2
Retinol palmitate 0.1
Hydrogenated retinol 0.1
Squalane 10.0
Isocetyl myristate 6.0
Glyceryl tri-2-ethylhexanoate 3.0
Macadamia nut oil 1.0
Dimethylpolysiloxane 0.2
Cetanol 5.0
POE (20) cetyl ether 1.0
Tetraoleic acid POE (40) Sorbit 0.5
Glyceryl monostearate 1.0
Hydrogenated soybean lecithin 0.2
B pyrrolidone carboxylic acid zinc salt 0.05
Sodium hyaluronate 0.01
Xanthan gum 0.1
1,3-butylene glycol 5.0
Citric acid 0.1
Sodium citrate 0.4
Preservative appropriate amount Purified water The remainder (preparation method) A and B are each heated to 80 ° C. and dissolved uniformly. While stirring A, B is added, stirred until uniform, and then cooled to room temperature to complete the preparation.
汚染防止用美容オイル
アスパラギン酸亜鉛塩 ０．００１（質量％）
ピコリン酸亜鉛塩 ０．００１
ミリスチン酸イソセチル １０．０
ホホバ油 ５．０
ブドウ種子油 １．０
天然ビタミンＥ ０．１
リノール酸レチノール ０．１
油溶性甘草エキス ０．１
スクワラン 残部
（調製方法）４０℃に加温し均一になるまで撹拌した後、室温まで冷却し、調製を終了とする。
Anti-pollution beauty oil zinc aspartate 0.001 (mass%)
Zinc picolinate 0.001
Isocetyl myristate 10.0
Jojoba oil 5.0
Grape seed oil 1.0
Natural vitamin E 0.1
Retinol linoleate 0.1
Oil-soluble licorice extract 0.1
The remainder of the squalane (preparation method) is heated to 40 ° C. and stirred until uniform, then cooled to room temperature, and the preparation is completed.
汚染防止用サンスクリーンクリーム
Ａ 流動パラフィン ７．０（質量％）
デカメチルシクロペンタシロキサン ３．０
セチルアルコール ４．０
縮合リシノール酸ヘキサグリセリル ０．５
ＰＯＥ（２０）セチルエーテル １．０
パラメトキシ桂皮酸オクチル ７．０
酸化チタン ３．０
セチル硫酸ナトリウム １．０
ステアロイルメチルタウリンナトリウム ０．３
Ｂ システイン亜鉛塩 ０．３
ヒスチジン亜鉛塩 ０．２
１，３−ブチレングリコール ５．０
キサンタンガム ０．３
ピロリドンカルボン酸ナトリウム ０．１
ツボクサエキス ０．１
スギナエキス ０．１
ローズマリーエキス ０．１
クエン酸 ０．２
クエン酸ナトリウム ０．３
防腐剤 適量
精製水 残部
（調製方法）Ａ、Ｂそれぞれ８０℃に加温し、均一に溶解する。Ａを撹拌しながら、Ｂを添加し、均一になるまで撹拌後、室温まで冷却し調製を終了する。
Sunscreen cream A for contamination prevention Liquid paraffin 7.0 (mass%)
Decamethylcyclopentasiloxane 3.0
Cetyl alcohol 4.0
Condensed ricinoleic acid hexaglyceryl 0.5
POE (20) cetyl ether 1.0
Octyl paramethoxycinnamate 7.0
Titanium oxide 3.0
Sodium cetyl sulfate 1.0
Stearoyl methyl taurine sodium 0.3
B Cysteine zinc salt 0.3
Histidine zinc salt 0.2
1,3-butylene glycol 5.0
Xanthan gum 0.3
Sodium pyrrolidonecarboxylate 0.1
Camellia extract 0.1
Horsetail extract 0.1
Rosemary extract 0.1
Citric acid 0.2
Sodium citrate 0.3
Preservative appropriate amount Purified water The remainder (preparation method) A and B are each heated to 80 ° C. and dissolved uniformly. While stirring A, B is added, stirred until uniform, and then cooled to room temperature to complete the preparation.
汚染防止用外用剤（軟膏製剤）
Ａ ＰＯＥ（３０）セチルエーテル ２．０（質量％）
モノステアリン酸グリセリル １０．０
流動パラフィン １０．０
白色ワセリン ５．０
セタノール ６．０
Ｂ グリシン亜鉛錯体 ５．０
プロピレングリコール １０．０
防腐剤 適量
精製水 残部
（調製方法）軟膏組成物の製造方法の常法に従い、乳化組成物を調製した。
External preparation for contamination prevention (ointment formulation)
A POE (30) cetyl ether 2.0 (mass%)
Glyceryl monostearate 10.0
Liquid paraffin 10.0
White petrolatum 5.0
Cetanol 6.0
B Glycine zinc complex 5.0
Propylene glycol 10.0
Preservative Appropriate amount Purified water The remainder (preparation method) An emulsified composition was prepared according to a conventional method for producing an ointment composition.
Claims (6)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014221042 | 2014-10-30 | ||
| JP2014221042 | 2014-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2016088929A true JP2016088929A (en) | 2016-05-23 |
Family
ID=56017547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015195544A Pending JP2016088929A (en) | 2014-10-30 | 2015-10-01 | Pollution preventing agent, and pollution preventing cosmetic or pollution preventing skin external preparation including the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2016088929A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019043886A (en) * | 2017-09-01 | 2019-03-22 | 日光ケミカルズ株式会社 | Discoloring inhibitor |
| WO2019159588A1 (en) * | 2018-02-16 | 2019-08-22 | 東洋紡株式会社 | Antipollution agent and topical skin composition |
| WO2019230233A1 (en) * | 2018-05-28 | 2019-12-05 | ロート製薬株式会社 | Devil's-claw extract and variety of compositions containing same, and production method for devil's-claw extract |
| JPWO2019078370A1 (en) * | 2017-10-20 | 2020-11-05 | ロート製薬株式会社 | Composition for improving skin disorders |
| KR20200128063A (en) | 2018-02-28 | 2020-11-11 | 도요보 가부시키가이샤 | Anti-pollution agent and skin external preparation |
| JP2021531247A (en) * | 2018-07-06 | 2021-11-18 | エニジェン カンパニー．，リミテッド． | A cosmetic composition for removing or adsorbing fine dust containing a peptide complex as an active ingredient. |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006022090A (en) * | 2004-06-08 | 2006-01-26 | Ajinomoto Co Inc | Inflammation inhibitor composed of pyrrolidonecarboxylic acid zinc salt |
| WO2007148831A1 (en) * | 2006-06-23 | 2007-12-27 | Ajinomoto Co., Inc. | Collagen synthesis promoter containing zinc as the active ingredient |
| JP2010132639A (en) * | 2008-11-10 | 2010-06-17 | Nikko Chemical Co Ltd | Dna damage inhibitor and matrix metalloprotease-1 production inhibitor |
-
2015
- 2015-10-01 JP JP2015195544A patent/JP2016088929A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006022090A (en) * | 2004-06-08 | 2006-01-26 | Ajinomoto Co Inc | Inflammation inhibitor composed of pyrrolidonecarboxylic acid zinc salt |
| WO2007148831A1 (en) * | 2006-06-23 | 2007-12-27 | Ajinomoto Co., Inc. | Collagen synthesis promoter containing zinc as the active ingredient |
| WO2007148832A1 (en) * | 2006-06-23 | 2007-12-27 | Ajinomoto Co., Inc. | Skin whitening agent containing zinc as active ingredient |
| JP2010132639A (en) * | 2008-11-10 | 2010-06-17 | Nikko Chemical Co Ltd | Dna damage inhibitor and matrix metalloprotease-1 production inhibitor |
Non-Patent Citations (5)
| Title |
|---|
| ARCH. DERMATOL. RES., vol. 306, JPN6020011234, 26 June 2014 (2014-06-26), pages 769 - 779, ISSN: 0004238598 * |
| JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, vol. 14, JPN6020011231, 2009, pages 53 - 55, ISSN: 0004238597 * |
| PARTICLE AND FIBRE TOXICOLOGY, vol. Vol.7:41, JPN6019031824, 2010, pages 1 - 13, ISSN: 0004097962 * |
| エアロゾル研究, vol. Vol.28(1), JPN6019031823, 2013, pages 34 - 41, ISSN: 0004097961 * |
| 大気環境学会誌, vol. Vol.37(2), JPN6020011235, 2002, pages 131 - 140, ISSN: 0004238599 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019043886A (en) * | 2017-09-01 | 2019-03-22 | 日光ケミカルズ株式会社 | Discoloring inhibitor |
| JPWO2019078370A1 (en) * | 2017-10-20 | 2020-11-05 | ロート製薬株式会社 | Composition for improving skin disorders |
| WO2019159588A1 (en) * | 2018-02-16 | 2019-08-22 | 東洋紡株式会社 | Antipollution agent and topical skin composition |
| CN111727033A (en) * | 2018-02-16 | 2020-09-29 | 东洋纺株式会社 | Stain-proofing agent and composition for external use on skin |
| KR20200121828A (en) | 2018-02-16 | 2020-10-26 | 도요보 가부시키가이샤 | Anti-pollution agent and composition for external skin |
| JPWO2019159588A1 (en) * | 2018-02-16 | 2021-01-28 | 東洋紡株式会社 | Anti-pollution agent and topical skin composition |
| KR20200128063A (en) | 2018-02-28 | 2020-11-11 | 도요보 가부시키가이샤 | Anti-pollution agent and skin external preparation |
| WO2019230233A1 (en) * | 2018-05-28 | 2019-12-05 | ロート製薬株式会社 | Devil's-claw extract and variety of compositions containing same, and production method for devil's-claw extract |
| JPWO2019230233A1 (en) * | 2018-05-28 | 2021-06-10 | ロート製薬株式会社 | Devil's Claw Extract, various compositions containing it, and method for producing Devil's Claw Extract |
| JP7461876B2 (en) | 2018-05-28 | 2024-04-04 | ロート製薬株式会社 | Devil's claw extract, various compositions containing same and method for producing devil's claw extract |
| JP2021531247A (en) * | 2018-07-06 | 2021-11-18 | エニジェン カンパニー．，リミテッド． | A cosmetic composition for removing or adsorbing fine dust containing a peptide complex as an active ingredient. |
| JP7273073B2 (en) | 2018-07-06 | 2023-05-12 | エニジェン カンパニー．，リミテッド． | Cosmetic composition for removing or adsorbing fine dust containing a peptide complex as an active ingredient |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016088929A (en) | Pollution preventing agent, and pollution preventing cosmetic or pollution preventing skin external preparation including the same | |
| JP2010132639A (en) | Dna damage inhibitor and matrix metalloprotease-1 production inhibitor | |
| WO2007092085A2 (en) | Fragranced therapeutic delivery system | |
| WO2007148832A1 (en) | Skin whitening agent containing zinc as active ingredient | |
| WO2005018598A1 (en) | Agent for eliminating singlet oxygen and composition using the same | |
| JP6721310B2 (en) | Anti-staining agent and anti-staining cosmetic or anti-skin external preparation containing the same | |
| CN106176569A (en) | A kind of prevent haze weather to the compositions of skin damage and application thereof | |
| IL262097A (en) | Cosmetic compositions for protection against air pollutants | |
| JP4377263B2 (en) | Cosmetics and external preparation for skin | |
| JP5883226B2 (en) | Singlet oxygen scavenger | |
| WO2018029673A1 (en) | Compositions comprising dead sea water and polysaccharides and uses thereof as skin protectants | |
| JP7534759B2 (en) | Antioxidants, antiglycation agents, hyaluronidase inhibitors, and cosmetics | |
| JP5279209B2 (en) | Topical skin preparation | |
| WO2015064681A1 (en) | Composition for external use | |
| JP2009269851A (en) | Inhibitor of prostaglandin e2 production and its utilization | |
| JP5966261B2 (en) | Composition for external use | |
| EP3532169A1 (en) | Novel method | |
| JP2016088866A (en) | CONTAMINANT PERMEATION PREVENTIVE FORMING α GEL STRUCTURE, AND CONTAMINANT PERMEATION-PREVENTING COSMETIC OR CONTAMINANT PERMEATION-PREVENTING SKIN EXTERNAL PREPARATION INCLUDING THE SAME | |
| CN105408306A (en) | Resorcinol derivatives and cosmetic application thereof | |
| EP0914815A1 (en) | Composition for external use for prevention of environmental stress | |
| JP6399545B2 (en) | Anti-oxidant derived from microalgae and cosmetic or skin external preparation containing the same | |
| JP6751868B2 (en) | Emulsified composition | |
| JP2012171917A (en) | Astringent | |
| JP2006095182A (en) | Cleaning agent extracted from natural product | |
| JPH0193520A (en) | Beautifying and whitening cosmetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151001 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180718 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180718 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190819 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191015 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200323 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200520 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200902 |